Noviral is a company founded as a result of the outbreak of Covid-19 with the vision to help Swedish companies get their employees back to the workplace quickly and safely. The company is founded by entrepreneurs and has had a medical advisory board since its inception, which assists with counseling and expertise in immunology. Noviral offers a variety of high-quality tests for Covid-19 as well as digital solutions for infection and symptom monitoring. The company also supports research and Swedish authorities through data collection.

Advisory Board

Alf Lindberg Image

Alf Lindberg, Prof

Dr. Alf Lindberg has vast experienced in vaccine development, both in research as a professor of clinical bacteriology at the university hospital Karolinska Institutet in Stockholm, Sweden and from the industry where Mr Lindberg has been the CSO and head of research for Wyeth Vaccines and Sanofi Pasteur. Mr Lindberg played an important part in developing Prevnar and is today active on multiple boards for biotechnology companies.

Mouna Esmaeilzadeh Image

Mouna Esmaeilzadeh, M.D, P.hD

Dr. Mouna Esmaeilzadeh is a doctor and has researched in neuroscience at the university hospital Karolinska Institutet, in Stockholm, Sweden. Dr. Esmaeilzadeh is an entrepreneur and a frequently invited keynote speaker on the future of health and preventative care.

Otto Stackelberg Image

Otto Stackelberg, MD, PhD

Mr Stackelberg is a vascular surgeon at Södersjukhuset, Stockholm, Sweden. Mr Stackelberg is currently working in the intensive care unit taking care of COVID-19 patients. PhD in epidemiology and biostatistics.

Sara Mangsbo Image

Sara Mangsbo

Mrs Mangsbo is a lecturer in Experimental Clinical Immunology and Assistant Lecturer in Protein Drugs at Uppsala University, Sweden. Mrs. Mangsbo is the Co-founder of Immuneed AB and Vivologica AB, and works as the Development Manager at Ultimovacs AB / ASA.

Lars-Olof Hansson, M.D

Dr. Lars-Olof Hansson is a specialist in clinical chemistry. From 2001-2004 he was the Medical Director of Clinical Chemistry and Pharmacology at the university hospital Akademiska hospital in Uppsala, Sweden and later Laboratory Manager of the Akademiska Laboratory. He was the acting director of KI Biobank and is now the senior clinical chemist at Karolinska University Laboratory. Furthermore, Mr. Hansson is responsible for the Swedish quality program for plasma protein within EQUALIS.

Management team